Media headlines about Alliqua Biomedical (NASDAQ:ALQA) have trended positive this week, Accern Sentiment reports. The research firm ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Alliqua Biomedical earned a news sentiment score of 0.29 on Accern’s scale. Accern also gave news coverage about the company an impact score of 44.1552390297862 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Shares of Alliqua Biomedical (NASDAQ:ALQA) traded up $0.01 on Friday, hitting $1.98. The stock had a trading volume of 42,455 shares, compared to its average volume of 121,330. Alliqua Biomedical has a 52 week low of $1.73 and a 52 week high of $8.48. The company has a market capitalization of $9.92, a P/E ratio of -0.21 and a beta of 1.85.

Alliqua Biomedical (NASDAQ:ALQA) last issued its earnings results on Thursday, November 9th. The company reported ($0.79) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.03) by ($0.76). Alliqua Biomedical had a negative return on equity of 110.42% and a negative net margin of 155.55%. sell-side analysts anticipate that Alliqua Biomedical will post -3.85 EPS for the current fiscal year.

ALQA has been the subject of a number of analyst reports. HC Wainwright set a $5.00 price objective on Alliqua Biomedical and gave the stock a “buy” rating in a research report on Wednesday, January 3rd. ValuEngine upgraded Alliqua Biomedical from a “sell” rating to a “hold” rating in a research report on Friday, October 6th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $8.20.

WARNING: This piece of content was reported by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another website, it was stolen and reposted in violation of United States and international copyright & trademark laws. The correct version of this piece of content can be read at https://www.dailypolitical.com/2018/01/20/favorable-news-coverage-somewhat-unlikely-to-impact-alliqua-biomedical-alqa-stock-price.html.

Alliqua Biomedical Company Profile

Alliqua BioMedical, Inc is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc and Choice Therapeutics, Inc The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds.

Insider Buying and Selling by Quarter for Alliqua Biomedical (NASDAQ:ALQA)

Receive News & Ratings for Alliqua Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliqua Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.